Yoon Y S, Jin D C, Yang C W, Kim S Y, Bang B K, Kim W I, Koh Y B
Department of Internal Medicine, Catholic University Medical College, Seoul, Korea.
Clin Transpl. 1993:275-83.
This study focuses on the beneficial effect of HLA matching on long-term graft survival rates in CsA-treated living primary kidney transplants at Catholic Medical Center, 1984 to 1993. 1. An impressive 26% difference in kidney graft survival was observed at 5 years between recipients who received 0 and 2 HLA-DR mismatches (79% vs 53%). 2. Five-year kidney graft survival rates in the 0, 1, 2, and 3-HLA-B+DR mismatches were 87%, 76%, 77%, and 74%, respectively, which was significantly different from 54% survival rates in the 4-HLA-B+DR mismatch group. 3. The 5-year kidney graft survivals in the 0, 1, 2, HLA-DR-mismatched living-nonrelated donor group were 84%, 76%, and 39%, respectively, which were significant differences. 4. The 5-year kidney graft survivals in the 0, 1, 2, HLA-DR-mismatched living-related donor group were 75%, 79%, and 72%, respectively, which were not significant. 5. The effect of HLA-A, B, A+B, A+DR, and A+B+DR mismatches showed little difference among the groups with different mismatch numbers. In conclusion, better matching for the HLA-DR, B+DR antigens significantly improved kidney graft survivals in our CsA-treated primary living-donor transplant recipients.
本研究聚焦于1984年至1993年在天主教医疗中心接受环孢素治疗的活体原发性肾移植中，HLA配型对长期移植物存活率的有益影响。1. 在接受0个和2个HLA-DR错配的受者中，5年时观察到肾移植存活率有令人印象深刻的26%的差异（79%对53%）。2. 0、1、2和3个HLA-B + DR错配组的5年肾移植存活率分别为87%、76%、77%和74%，这与4个HLA-B + DR错配组54%的存活率有显著差异。3. 0、1、2个HLA-DR错配的非亲属活体供者组的5年肾移植存活率分别为84%、76%和39%，存在显著差异。4. 0、1、2个HLA-DR错配的亲属活体供者组的5年肾移植存活率分别为75%、79%和72%，无显著差异。5. HLA-A、B、A + B、A + DR和A + B + DR错配的影响在不同错配数的组间差异不大。总之，在我们接受环孢素治疗的原发性活体供者移植受者中，更好地匹配HLA-DR、B + DR抗原显著提高了肾移植存活率。
